Numab Therapeutics raises 100 million Swiss francs

Numab Therapeutics has raised a total of 100 million Swiss francs as part of an oversubscribed Series C financing round, which was led by the Danish pharma group Novo Holdings and the Zug-based investment firm HBM Partners. A diverse range of other investors also took part in the process, including the Dutch venture capitalists Forbion. Nanna Lüneborg from Novo Ventures, Matthias Fehr from HBM Partners and Carlo Incerti from Forbion will now all join the company’s Board of Directors.

Numab Therapeutics is developing immunotherapies on the basis of antibodies to treat cancer and inflammatory diseases. Using this fresh capital injection, the company intends to accelerate the development of its leading cancer drug NM21-1480 in addition to expanding its application areas, among other measures. Moreover, the further development of the product pipeline for multi-specific antibodies is also to be advanced.

“We are delighted to receive the support of such a renowned group of investors that also shares our vision for the future of the company”, comments David Urech, CEO and founder von Numab Therapeutics, in a press release covering the investment and financing round. Thanks to this fresh capital, the company will be in a position to accelerate and significantly expand clinical development, Urech explains.